Latest News - Amgen

Thursday, October 18, 2018

Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europe

Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission …

Read the full story

Friday, November 17, 2017

Amgen Launches The Enbrel Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector

Amgen's Enbrel Mini with AutoTouch is now available in the United States. Awarded the Arthritis Foundation Ease of Use Commendation, this new and innovative delivery system provides an additional …

Read the full story

Monday, November 07, 2016

FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis

The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric pat…

Read the full story

Friday, September 23, 2016

FDA Approves Humira Biosimilar

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following ind…

Read the full story

Wednesday, August 31, 2016

FDA Approves Enbrel Biosimilar

The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no …

Read the full story

Wednesday, April 13, 2016

Psoriasis Market Poised for Growth Spurt by 2024

The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a new report from GlobalData. The market will rise from $6.6 billion in 2014 to over …

Read the full story

Friday, March 18, 2016

Study Links Psoriasis to Bone Loss. Is IL-17 to Blame?

Psoriasis is linked to widespread bone loss, according to Researchers from the Genes, Development and Disease Group at the Spanish National Cancer Research Centre (CNIO) in Madrid. The new study, w…

Read the full story

Wednesday, October 28, 2015

Imlygic Approved for Melanoma; Available in a Week

The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of …

Read the full story